Journal of Surgical Oncology. 2008 Sep 15;98(4):268-72. [Link]
Deraco M, Bartlett D, Kusamura S, Baratti D.
Department of Surgery, National Cancer Institute, Milan, Italy. email@example.com
Diffuse malignant peritoneal mesothelioma (DMPM) has been traditionally regarded as a rapidly lethal disease. Recently, several independent prospective trials have reported improved survival with an intensive loco-regional treatment strategy including cytoreductive surgery (CRS) along with peri-operative intra-peritoneal chemotherapy (PIC). However, most of the surgical data comes from mono-institutional phase I or II studies and there is a broad range of variability regarding inclusion criteria, cytoreductive surgical procedures, drugs, temperatures and methods of delivering the heated chemotherapy (open vs. closed abdomen). This manuscript critically analyze and discuss the results of a group of health care providers trying to achieve a consensus statement in the management of this group of patients. The main conflicting points regarding preoperative evaluation, patient eligibility, combined treatment methodology, postoperative follow-up and future investigational perspectives were summarized as a list of multiple-choice questions. A questionnaire was placed on the website of the “5th International Workshop on Peritoneal Surface Malignancies” and the group members voted via internet. The results were presented for further debate during a dedicated session of the Workshop. The general treatment guidelines and future investigational perspectives were defined.
Keywords: consensus, peritoneal mesothelioma, cytoreductive surgery, hyperthermic intra-peritoneal chemotherapy, HIPEC